Caption Management’s Protagonist Therapeutics PTGX Stock Holding History

Caption Management’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.24M	Buy	+11,800	New	+$1.04M	0.01%	949
2025 Q3	–	Sell	-143,000	Closed	-$7.9M	–	1970
2025 Q2	$7.9M	Sell	143,000 -50,900	-26%	-$2.44M	0.09%	272
2025 Q1	$9.38M	Buy	193,900 +104,700	+117%	+$4.39M	0.09%	221
2024 Q4	$3.44M	Hold	89,200	–	–	0.03%	503
2024 Q3	$4.01M	Buy	+89,200	New	+$3.6M	0.06%	355
2022 Q3	–	Sell	-80,000	Closed	-$633K	–	1782
2022 Q2	$633K	Buy	+80,000	New	+$967K	0.01%	1018
2022 Q1	–	Sell	-233,600	Closed	-$7.99M	–	1844
2021 Q4	$7.99M	Sell	233,600 -3,900	-2%	-$123K	0.09%	315
2021 Q3	$4.21M	Buy	+237,500	New	+$10.1M	0.05%	524

Other funds holding PTGX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Caption Management's PTGX Position: Q1 2025 in Review

Caption Management sold out of Protagonist Therapeutics (PTGX) in Q1 2025, closing a stake of 98,934 shares — an estimated $4.15M sold.

Caption Management first reported a position in PTGX in Q3 2021 and held it in 10 quarters. The position peaked at $6.59M in Q4 2021. 275 funds tracked by Wall St. Rank hold PTGX as of Q1 2025.

Caption Management reported no remaining Protagonist Therapeutics position as of Q1 2025 after selling out during the quarter.
Caption Management sold 98,934 Protagonist Therapeutics shares in Q1 2025, an estimated $4.15M.
Caption Management first reported a position in Protagonist Therapeutics in Q3 2021 and held it in 10 quarters.
Caption Management's Protagonist Therapeutics position peaked at $6.59M in Q4 2021.
275 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2025.

Based on Caption Management's 13F filing for Q1 2025, filed 15 May 2025.